


# 볼리브리스의 Sustained Efficacy<sup>1-3</sup>




- 효과와 안전성 평가를 위한 Cluster Analyses 입니다.
- 볼리브리스는 6MWD와 SAE 동시 평가 시 효과와 안전성 1위를 차지하여 우수한 Efficacy 및 Acceptability를 보였습니다.<sup>4</sup>


## Cluster Analyses (네트워크 메타분석 결과)<sup>4</sup>




Placebo: 6MWD 1.5%, clinical worsening 6.5%  
 Bosentan: 6MWD 92.5%, clinical worsening 72.3%  
 Ambrisentan: 6MWD 78.8%, clinical worsening 63.5%  
 Macitentan: 6MWD 32.5%, clinical worsening 27.0%



Placebo: 6MWD 1.5%, Death 27.8%  
 Bosentan: 6MWD 92.5%, Death 70.5%  
 Ambrisentan: 6MWD 78.8%, Death 67.3%  
 Macitentan: 6MWD 32.5%, Death 19.8%



Placebo: 6MWD 1.5%, SAE 29.8%  
 Bosentan: 6MWD 92.5%, SAE 46.0%  
 Ambrisentan: 6MWD 78.8%, SAE 79.8%  
 Macitentan: 6MWD 32.5%, SAE 57.8%



Placebo: 6MWD 1.5%, all-cause discontinuation 16.5%  
 Bosentan: 6MWD 92.5%, all-cause discontinuation 63.5%  
 Ambrisentan: 6MWD 78.8%, all-cause discontinuation 78.8%  
 Macitentan: 6MWD 32.5%, all-cause discontinuation 30.3%

\* Sitaxsentan has been withdrawn from the market

Adapted from Duo-ji MM, et al. Int J Cardiol 2017;234:90-8

